Get the Stockscreener App
62.95
0.27%
-0.17
After Hours:
62.71
-0.24
-0.38%
Dexcom Inc stock is traded at $62.95, with a volume of 4.73M.
It is down -0.27% in the last 24 hours and down -2.01% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$63.12
Open:
$62.69
24h Volume:
4.73M
Relative Volume:
0.97
Market Cap:
$24.23B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
30.08
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
-0.25%
1M Performance:
-2.01%
6M Performance:
-4.92%
1Y Performance:
-6.59%
1-Day Range:
$62.00
$63.70
1-Week Range:
$61.64
$66.44
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
62.95 | 24.64B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
101.05 | 174.29B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
345.88 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
88.12 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
63.82 | 91.83B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 44.90B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
Greenup Street Wealth Management Invests in DexCom - National Today
Risk Analysis: Can DexCom Inc be the next market leader2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Trend Recap: Can DexCom Inc be the next market leaderPortfolio Profit Report & High Accuracy Trade Alerts - baoquankhu1.vn
Wells Fargo Maintains DexCom (DXCM) Overweight Recommendation - MSN
DexCom (XSWX:DXCM) Other Assets for Banks - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to drive U.S. inves - AD HOC NEWS
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy - ChartMill
DexCom (DXCM) Is Up 5.5% After New G7 Reimbursement Wins And CEO Transition PlansWhat's Changed - Sahm
DXCM (DexCom) Future Policy Benefits - GuruFocus
Alert from law firm on Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Goldman Sachs Adjusts Price Target on DexCom to $82 From $83, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Shareholders to Connect - ACCESS Newswire
At US$63.21, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Devon Energy Corp stock: Merger clearance sparks scale questions for investors - AD HOC NEWS
Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM - MarketBeat
Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nisa Investment Advisors Reduces DexCom Stake by Over 50% - National Today
Nisa Investment Advisors LLC Sells 20,529 Shares of DexCom, Inc. $DXCM - MarketBeat
Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom Stock Hits Day Low of $62 Amid Price Pressure - Markets Mojo
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Radcliffe Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - GuruFocus
Devon Energy Corp Stock: Strategic Positioning in North American Oil and Gas Amid Market Volatility - AD HOC NEWS
Is DexCom (DXCM) Fairly Priced After Recent Share Price Weakness? - Yahoo Finance
DexCom Inc (DXCM) Stock Price, Quote, News & History - Benzinga
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook By Investing.com - Investing.com Australia
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook - Investing.com India
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
SWS Partners Has $3.69 Million Stake in DexCom, Inc. $DXCM - MarketBeat
Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM - MarketBeat
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves - Sahm
BNY Mellon Large Cap Securities Fund, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pallas Capital Advisors LLC Decreases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Pressures - Markets Mojo
DexCom Inc. stock rises Tuesday, still underperforms market - MarketWatch
Soleus Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom Inc (DXCM) Stock Price Down 5.81% on Mar 30 - GuruFocus
DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
1.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):